

REFERENCES

- Amnuoypol, S. 2004. Cytotoxic bistetrahydroisoquinoline alkaloids from the Thai marine sponge, *Xestospongia* sp. Degree of Doctor of Philosophy in Pharmaceutical Chemistry and Natural Products. Pharmaceutical science. Chulalongkorn University.
- Amnuoypol, S., Suwanborirux, K., Pummangura, S., Kubo, A., Tanaka, C., and Saito, N. 2004. Chemistry of renieramycins. part 5. Structure elucidation of renieramycin-type derivatives O, Q, R, and S from Thai marine sponge *Xestospongia* species pretreated with potassium cyanide. J. Nat. Prod. 67 (6): 1023-1028.
- Arai, T., Takahashi, K., and Kubo, A. 1977. New antibiotics, saframycins A, B, C, D, and E. J. Antibiot. 30 (11): 1015-1018.
- Arai, T., Takahashi, K., Ishiguro, K., and Yazawa, K. 1980. Increase production of saframycin A and isolation of saframycin S. J. Antibiot. 33 (9): 951-960.
- Asaoka, T., Yazawa, K., Mikami, Y., Arai, T. and Takahashi, K. 1982. A new saframycin, saframycin R. J. Antibiot. 35 (12): 1708-1710.
- Avila, C., Ballesteros, M., Cimino, G., Crispino, A., Gavagnin, M., and Sodano, G. 1990. Biosynthetic origin and anatomical distribution of the main secondary metabolites in the nudibranch mollusk *Doris verrucosa*. Comp. Biochem. Physiol. 97B (2): 363-368.
- Bidgrain, 2005. *Jorunna funebris* description and characteristic [online]. Available from: http://vieocean.free.fr/runseaslug/a_joru_funebris.htm[2006, April 9].
- Bonfanti, M., Caretti, G., La Valle, E., Sousa Faro, J. M. F., Faircloth, G., Mantonvani, R., and D' Incalci, M. 1999. Effect of ecteinascidin-743 (ET-743) on the interaction between DNA binding proteins and DNA. Anti-Cancer Drug Res. 14: 179-186.
- Celis, J. E., Kruhoffer, M., Gromova, I., Frederiksen, C., Osterguard, M., Thykjaer, T., Gromov, P., Yu, J., Pa'lsdo'ttir, H., Magnusson, N., and Orntoft, T. F. 2000. Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FF₂BS Letters. 480: 2-16.

- Chen, J., Chen, X., Bois-Choussy, M., and Zhu, J. 2005. Total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 128: 87-89.
- Corey, E. J., Gin, D. Y., and Kania, R. S. 1996. Enantioselective total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 118: 9202-9203.
- Davidson, B. S. 1992. Renieramycin G, a new alkaloid from the sponge *Xestospongia caycedoi*. Tetrahedron Lett. 33 (26): 3721-3724.
- Endo, A., Yanagisawa, A., Abe, M., Tohma, S., Kan, T., and Fukuyama, T. 2002. Total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 124: 6552-6554.
- Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., and D'Incalci, M. 2001. Ecteinascidin-743 (Et-743), a natural marine compound with a unique mechanism of action. Eur. J. Cancer. 37 (1): 97-105.
- Erba, E., Bergamaschi, D., Ronzoni, S., Faretta, M., Bassano, L., Cappella, P., Valoti, G., Riavazzi, R., Jimeno, J., Faircloth, G., D'Incalci, M., and Nergri, M. 1998. Mode of action of ecteinascidin 743, a natural marine compound with antitumoral activity. Ann. Oncol. 9 Suppl. 2: 139.
- Fontana, A., Cavaliere, P., Wahidulla, S., Naik, C. G., and Cimino, G. 2000. A new antitumor isoquinoline alkaloid from the marine nudibranch *Jorunna funebris*. Tetrahedron. 56: 7305-7308.
- Frincke, J. M., and Faulkner, D. J. 1982. Antimicrobial metabolites of the sponge *Reniera* sp. J. Am. Chem. Soc. 104: 265-269.
- Garcia-Rocha, M., Garcia-Gravalos, MD., and Avila, J. 1996. Characterisation of antimetabolic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Brit. J. Cancer. 73: 875-883.
- Ghielmini, M., Colli, E., Erba, E., Bergamaschi, D., Pampallona, S., Jimeno, J., Faircloth, G., and Sessa, C. 1998. *In vitro* schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (Et-743). Ann. Oncol. 9: 989-993.
- Haviv, I., and Campbell, I. G. 2002. DNA microarrays for assessing ovarian cancer gene expression. Molecular and Cellular Endocrinology. 191: 121-126.
- He, H., and Faulkner, D. J. 1989. Renieramycins E and F from the sponge *Reniera* sp.: reassignment of the stereochemistry of the renieramycins. J. Org. Chem. 54: 5822-5824.

- Hendriks, H. R., Fiebig, H. H., Giavazzi, R., Langdon, S. P., Jimeno, J. M., and Faircloth, G. T. 1999. High antitumor activity of ET743 against human tumor xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann. Oncol. 10: 1233-1240.
- Henriquez, R., Faircloth, G., and Cuevas, C. 2005. Ecteinascidin 743 (ET-743; yondelisTM, aplidin, and kahalslide F. Cragg, G. M., Kingston, D. G. I., and Newman, D. J. Anticancer agent from natural products, pp. 215-236. London: CRC.
- Hill, G. C., and Remers, W. A. 1991. Computer simulation of the binding of saframycin A to d(GATGCATC)₂. J. Med. Chem. 34: 1990-1998.
- Hooper, J. N. A. 2000. Spongicide: Guide to sponge collection and identification [online]. Available from: <http://www.qmuseum.qld.gov.au/organisation/sections/SessileMarineInvertebrates/index.asp>[2007, April 12].
- Irschik, H., Trowitzsch-kienast, W., Gerth, K., Hofle, G., and Reichenbach, H. 1988. Saframycin Mx1, a new natural saframycin isolated from a myxobacterium. J. Antibiot. 91 (8): 993-998.
- Ishiguro, K., Sakiyama, S., Takahashi, K., and Arai, T. 1978. Mode of action of saframycin A, a novel heterocyclic quinone antibiotic, inhibition of RNA synthesis *in vivo* and *in vitro*. Biochemistry. 17 (13): 2545-2550.
- Jimeno, J., Faircloth, G., Fernandez Sousa-Faro, J. M., Scheuer, P., and Rinehart, K. 2004. New marine derived anticancer therapeutics-a journey from the sea to clinical trials. Marine Drugs. 2: 14-29.
- Jin, S., Lin, Y., Magro, P. G., and Scotto, K. W. 1999. Regression of MDR1 gene transcription by ecteinascidin 743. Proc. Am. Assoc. Cancer Res. 40: 314.
- Kaneda, S., Hour-Young, C., Yazawa, K., Takahashi, K., Mikami, Y. and Arai, T. 1987. Biological activities of newly prepared saframycins. J. Antibiot. 90 (11): 1640-1642.
- Kishi, K., Yazawa, K., Takahashi, K., Mikami, Y., and Arai, T. 1984. Structure-activity relationships of saframycins. J. Antibiot. 37 (8): 847-852.
- Kuo, W. P., Whipple, M. E., Sonis, S. T., Ohno-Machado, L., and Jenssen, T. 2002. Gene expression profiling by DNA microarrays and its application to dental research. Oral Oncology. 38: 650-656.

- Lamartine, J. 2006. The benefits of DNA microarrays in fundamental and applied bio-medicine. Materials Science and Engineering C. 26: 354-359.
- Lane, J. W., Estevez, A., Mortara, K., Callan, O., Spencer, J. R., and Williams, R. M. 2006. Antitumor activity of tetrahydroisoquinoline analog 3-*epi*-jorumycin and 3-*epi*-renieramycin G. Bioorganic & Medicinal Chemistry Letter. 16: 3180-3183.
- Lown, J. W., Joshua, A. V., and Lee, J. S. 1982. Molecular mechanisms of binding and single-strand scission of deoxyribonucleic acid by antitumor antibiotics saframycins A and C. Biochemistry. 21 (3): 419-428.
- Lown, J. W., Hanstock, C. C., Joshua, A. V., Arai, T., and Takahashi, K. 1983. Structure and conformation of saframycin R determined by high field ^1H and ^{13}C NMR and its interactions with DNA in solution. J. Antibiot. 36 (9): 1184-1194.
- Manning, A. T., Garvin, J. T., Shahbazi, R. I., Miller, N., McNeill, R. E., and Kerin, M. J. 2007. Molecular profiling techniques and bioinformatics in cancer research. EJSO. 33: 255-265.
- Mantonvani, R., La Valle, E., Sousa Faro, J. M. F., Faircloth, G., and D'Incalci, M. 1998. Effect of ecteinascidin-743 (Et-743) on the interaction between transcription factors and DNA. Ann. Oncol. 9 Suppl. 2: 133-139.
- Martinez, E. J., and Corey, E. J. 2000. A new, more efficient, and effective process for the synthesis of key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents. Org. Lett. 2 (7): 993-996.
- Martinez, E. J., Owa, T., Schreiber, S. L., and Corey, E. J. 1999. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. Proc. Natl. Acad. Sci. U.S.A. 96: 3496-3501.
- Martinez, E. J., Corey, E. J., and Owa, T. 2001. Antitumor activity-and gene expression-based profiling of ecteinascidin Et 473 and phthalascidin pt 650. Chemistry & Biology. 8 (12): 1151-1160.
- Mikami, Y., Takahashi, K., Yazawa, K., Hour-Young, C., and Arai, T. 1988. Structural studies on minor components of saframycin group antibiotics saframycins F, G and H. J. Antibiot. 91 (6): 734-740.

- Moore, R. M., II, Seaman, F. C., Wheelhouse, R. T., and Hurley, L. H. 1998. Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2. J. Am. Chem. Soc. 120: 2490-2491.
- Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application of proliferation and cytotoxicity assays. J. Immunol. Methods. 65: 55-63.
- Myers, A. G. and Plowright, A. T. 2001. Synthesis and evaluation of bishydroquinone derivatives of (-)-saframycin A: identification of a versatile molecular template template imparting potent antiproliferative activity. J. Am. Chem. Soc. 123: 5114-5115.
- Oku, N., Matsunaga, S., Van Soest, R. W. M., and Fusetani, N. J. 2003. Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge *Neopetrosia* sp. J. Nat. Prod. 66: 1136-1139.
- Parameswaran, P. S., Naik, C. G., Kamat, S. Y., and Pramanik, B. N. 1998. Renieramycins H and I, two novel alkaloids from the sponge *Haliclona cribricutis* Dendy. Indian J. Chem. 37B: 1258-1263.
- Pechenik, J. A. 1996. The mollusks. Biology of the invertebrates. 3rd ed. p. 283. London: Wm. C. Brown Publishers.
- Pettit, G. R., Knight, J. C., Collins, J. C., Herald, D. L., Pettit, R. R., Boyd, M. R., and Young, V. G. 2000. Antineoplastic agents 430. Isolation and structure of cribrostatins 3, 4 and 5 from the Republic of Maldives *Cribrochalina* species. J. Nat. Prod. 63: 793-798.
- Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., and Kohn, K. W. 1996. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean Tunicate *Ecteinascidia turbinata*. Biochemistry. 35 (41): 13303-13309.
- Proksh, P. 1994. Defensive roles for secondary metabolites from marine sponges and sponge-feeding nudibranch. Toxicon. 32 (6): 639-655.
- Puthongking, P., Patarapanich, C., Amnuoypol, S., Suwanborirux, K., Kubo, A., and Saito, N. 2006. Chemistry of ecteinascidins part 2 preparation of 6'-O -acyl derivatives of stable ecteinascidin and evaluation of cytotoxicity. Chem. Pharm. Bull. 54 (7): 1010-1016.

- Rao, K. E. and Lown, J. W. 1990. Mode of action of saframycin antitumor antibiotics: sequence selectivities in the covalent binding of saframycins A and S to deoxyribonucleic acid. Chem. Res. Toxicol. 3: 262-267.
- Rao, K. E., and Lown, W. 1992. DNA sequence selectivities in the covalent bonding of antibiotic saframycins Mx1, Mx2, A, and S deduced from MPE⁺ Fe(II) footprinting and exonuclease III stop assay. Biochemistry. 31: 12076-12082.
- Rinehart, K. L., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F., Li, L. H., and Martin, D. G. 1990a. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate *Ecteinascidia turbinata*. J. Org. Chem. 55: 4512-4515.
- Rinehart, K. L., Holt, T. G., Fregeau, N. L., Keifer, P. A., Wilson, G. R., Perun Jr., T. J., Sakai, R., Thompson, A. G., Stroh, J. G., Shield, L. S., Seigler, D. S., Li, L. H., Martin, D. G., Grimmelikhuijzen, J. P. G., and Gade, G. 1990b. Bioactive compounds from aquatic and terrestrial sources. J. Nat. Prod. 53 (4): 771-792.
- Rinehart, K. L. 2000. Antitumour compounds from tunicates. Med. Res. Rev. 20 (1): 1-27.
- Saito, N., Tanaka, C., Koizumi, Y., Suwanborirux, K., Amnuoypol, S., Pummangura, S., and Kubo, A. 2004. Chemical of renieramycins part 6: transformation of renieramycin M into jorumycin and renieramycin J including oxidative degradation products, mimosamycin, renierone, and renierol acetate. Tetrahedron. 60: 3873-3881.
- Saito, N., Sakai, H., Suwanborirux, K., Pummangura, S., and Kubo, A. 2001. ¹³C NMR spectral assignment of 5-hydroxy-1,5-imino-3-benzazocin-4,7,10-trione derivatives: the revised structure of renieramycin H. Heterocycles 55: 21-28.
- Sakai, R., Rinehart, K. L., Guan, Y., and Wang, A. H.-J. 1992. Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities *in vivo*. Proc. Natl. Acad. Sci. 89: 11456-11460.
- Sakai, R., Jares-Erijman, E. A., Manzanares, I., Silva Elipe, M. V., and Rinehart, K. L. 1996a. Ecteinascidins: putative biosynthetic precursors and absolute stereochemistry. J. Am. Chem. Soc. 118: 9017-9023.
- Sakai, R., Rinehart, K. L., Kishore, V., Kundu, B., Faircloth, G., Gleer, J. B., Carney, J. R., Namikoshi, M., Sung, F., Hughes, R. G., Gravalos, D. G., Garcia de

- Quesada, T., Wilson, G. R., and Heid, R. M. 1996b. Structure-activity relationships of the didemnins. J. Med. Chem. 39: 2819-2834.
- Scott, J. L., and Williams, R. M. 2002. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. Chem. Rev. 102: 1669-1730.
- Seaman, F. C., and Hurley, L. H. 1998. Molecular basis for the DNA sequence selectivity of ecteinascidin 736 and 743: evidence for the dominant role of direct readout via hydrogen bonding. J. Am. Chem. Soc. 120: 13028-13041.
- Shibuya, K., and Shiratsuchi, M. 1995. Chemoselective removal of allylic formyloxy group using SmI_2 . Synthetic Communications. 25 (3): 431-449.
- Spencer, J. R., Sendzik, M., Oeh, J., Sabbatini, P., Dalrymple, S. A., Magill, C., Kim, H. M., Zhang, P., Squires, N., Moss, K. G., Sukbuntherng, J., Graupe, D., Eksterowicz, J., Young, P. R. Myers, A. G. and Green, M. J. 2006. Evaluation of antitumor properties of novel saframycin analogs *in vitro* and *in vivo*. Bioorganic & Medicinal Chemistry Letters. 16: 4884-4888.
- Suwanborirux, K., Charupant, K., Amnuoypol, S., Pummangura, S., Kubo, A., and Saito, N. 2002. Ecteinascidins 770 and 786 from the Thai tunicate *Ecteinascidia thurstoni*. J. Nat. Prod. 65: 935-937.
- Suwanborirux, K., Amnuoypol, S., Plubrukarn, A., Pummangura, S., Kubo, A., Tanaka, C., and Saito, N. 2003. Chemistry of renieramycins. part 3. Isolation and structure of stabilized renieramycin type derivatives possessing antitumor activity from Thai sponge *Xestospongia* species, pretreated with potassium cyanide. J. Nat. Prod. 66 (11): 1441-1446.
- Takahashi, K., Yazawa, K., Kishi, K., Mikami, Y., Arai, T., and Kubo, A. 1982. Microbial conversion of saframycin A to 25-dihydrosafamycin A and 21-decyano-25-dihydrosafamycin A (25-dihydrosafamycin B) and their biological activities. J. Antibiot. 35 (2): 196-202.
- Takebayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G., and Pommier, Y. 1999. Poisoning of human DNA topoisomerase I by ecteinascidin 743 and anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. 96: 7102-7196.
- Takebayashi, Y., Pourquier, P., Zimonjic, D. B., Nakayama, K., Emmert, S., Ueda, T., Urasaki, Y., Kanzaki, A., Akiyama, S., Popescu, N., Kraemer, K. H., and Pommier, Y. 2001. Antiproliferative activity of ecteinascidin 743 is

- dependent upon transcription - coupled nucleotide-excision repair. Nat. Med. 7: 961.
- Valoti, G., Nicoletti, M.I., Pellegrino, A., Jimeno, A., Jimeno, J., Hendriks, H., D'Incalci, M., Faircloth, G., and Giavazzi, R. 1998. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res. 4: 1977-1983.
- Wright, A. E., Forleo, A. D., Gunawardana, P. G., Gunasekera, P. S., Koehn, E. F., and McConnell, J. O. 1990. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian *Ecteinascidia turbinata*. J. Org. Chem. 55: 4508-4512.
- Yazawa, K., Asaoka, T., Takahashi, K., Mikami, Y., and Arai, T. 1982. Bioconversions of saframycin A specific to some genera of actinomycetes. J. Antibiot. 35 (7): 915-917.
- Yazawa, K., Takahashi, K., Mikami, Y., Arai, T., Saito, N., and Kubo, A. 1986. Isolation and structural elucidation of new saframycins Y3, Yd-1, Yd-2, Ad-1, Y2b and Y2b-d. J. Antibiot. 39 (12): 1639-1650.
- Zewail-Foote, M., and Hurley, L. H. 1999. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. 42 (14): 2493-2497.
- Zheng, S., Chan, C., Furuuchi, T., Wright, B. J. D., Zhou, B., Guo, J., and Danishefsky, S. J. 2006. Stereospecific formal total synthesis of ecteinascidin 743. Angew. Chem. Int. Ed. 45: 1754-1759.

APPENDICES




Figure 7 The FAB mass spectrum of jorunnamycin A.




Figure 8 The UV spectrum of jorunnamycin A in MeOH.




Figure 9 The circular dichroism spectrum of jorunnamycin A in MeOH.




Figure 10 The IR spectrum of jorunnamycin A (CHCl_3).




Figure 11 The 500 MHz ^1H NMR spectrum of jorunnamycin A in CDCl_3 .




Figure 12 The 500 MHz ^1H - ^1H COSY spectrum of jorunnamycin A in CDCl_3 .




Figure 15 The 500 MHz HMQC spectrum of jorunnamycin A in CDCl_3 .




Figure 16 The 500 MHz HMQC spectrum of jorunnamycin A in CDCl_3 .
(expanded from δ_{H} 3.0-4.4 ppm and δ_{C} 53.2-64.6 ppm)




Figure 17 The 500 MHz HMBC spectrum of jorunnamycin A in CDCl_3 .




Figure 18 The 500 MHz HMBC spectrum of jorunnamycin A in CDCl_3 .
(expanded from δ_{H} 1.2-2.4 ppm and δ_{C} 124.0-186.8 ppm)




Figure 19 The 500 MHz HMBC spectrum of jorunnamycin A in CDCl_3 .
(expanded from δ_{H} 2.25-4.25 ppm and δ_{C} 20.0-65.0 ppm)




Figure 20 The 500 MHz HMBC spectrum of jorunnamycin A in CDCl_3 .
(expanded from δ_{H} 2.25-4.25 ppm and δ_{C} 115.0-186.8 ppm)





Figure 21 The 500 MHz NOESY spectrum of jorunnamycin A in CDCl₃.






Figure 22 The FAB mass spectrum of jorunnamycin B.




Figure 23 The UV spectrum of jorunnamycin B in MeOH




Figure 24 The circular dichroism spectrum of jorunnamycin B in MeOH.




Figure 25 The IR spectrum of jorunnamycin B (CHCl_3).




Figure 26 The 300 MHz ^1H NMR spectrum of jorunnamycin B in CDCl_3 .




Figure 27 The 300 MHz ^1H - ^1H COSY spectrum of jorunnamycin B in CDCl_3 .




Figure 28 The 75 MHz ¹³C NMR spectrum of jorunnamycin B in CDCl₃.




Figure 29 The 75 MHz ¹³C NMR and DEPT-135 spectra of jorunnamycin B in CDCl₃.




Figure 30 The 300 MHz HMQC spectrum of jorunnamycin B in CDCl_3 .




Figure 31 The 300 MHz HMBC spectrum of jorunnamycin B in CDCl_3 .




Figure 32 The 300 MHz HMBC spectrum of jorunnamycin B in CDCl_3 .
(expanded from δ_{H} 1.0-4.5 and 10.2-12.4 ppm and δ_{C} 100-200 ppm)





Figure 33 The 300 MHz HMBC spectrum of jorunnamycin B in CDCl_3 .
(expanded from δ_{H} 1.0-4.5 ppm and δ_{C} 30-70 ppm)






Figure 34 The 300 MHz NOESY spectrum of jorunnamycin B in CDCl_3 .




Figure 35 The FAB mass spectrum of jorunnamycin C.




Figure 36 The UV spectrum of jorunnamycin C in MeOH.




Figure 37 The circular dichroism spectrum of jorunnamycin C in MeOH.




Figure 38 The IR spectrum of jorunnamycin C (CHCl₃).




Figure 39 The 500 MHz ^1H NMR spectrum of jorunnamycin C in CDCl_3 .




Figure 40 The 500 MHz ^1H - ^1H COSY spectrum of jorunnamycin C in CDCl_3 .




Figure 41 The 125 MHz ^{13}C NMR spectrum of jorunnamycin C in CDCl_3 .




Figure 42 The 125 MHz ^{13}C NMR, DEPT-135 and DEPT-90 spectra of jorunnamycin C in CDCl_3 .




Figure 43 The 500 MHz HMQC spectrum of jorunnamycin C in CDCl_3 .




Figure 44 The 500 MHz HMBC spectrum of jorunnamycin C in CDCl_3 .




Figure 45 The 500 MHz HMBC spectrum of jorunnamycin C in CDCl₃.
(expanded from δ_H 0.8-4.4 ppm and δ_C 8.0-64.0 ppm)




Figure 46 The 500 MHz HMBC spectrum of jorunnamycin C in CDCl₃.
(expanded from δ_H 0.8-4.4 ppm and δ_C 100-185 ppm)





Figure 47 The 500 MHz NOESY spectrum of jorunnamycin C in CDCl_3 .






Figure 48 The ESI-TOF mass spectrum of renieramycin M.




Figure 49 The 300 MHz ¹H NMR spectrum of renieramycin M in CDCl₃.




Figure 50 The 75 MHz ¹³C NMR spectrum of renieramycin M in CDCl₃.




Figure 51 The ESI-TOF mass spectrum of renieramycin N.




Figure 52 The 300 MHz ¹H NMR spectrum of renieramycin N in CDCl₃.




Figure 53 The 75 MHz ^{13}C NMR spectrum of renieramycin N in CDCl_3 .




Figure 54 The ESI-TOF mass spectrum of renieramycin O.




Figure 55 The 300 MHz ¹H NMR spectrum of renieramycin O in CDCl₃.




Figure 56 The 75 MHz ¹³C NMR spectrum of renieramycin O in CDCl₃.




Figure 57 The ESI-TOF mass spectrum of renieramycin Q.




Figure 58 The 300 MHz ¹H NMR spectrum of renieramycin Q in CDCl₃.




Figure 59 The ESI-TOF mass spectrum of mimosamycin.




Figure 60 The 300 MHz 1H NMR spectrum of mimosamycin in $CDCl_3$.




Figure 61 The 75 MHz ¹³C NMR spectrum of mimosamin in CDCl₃.




Figure 62 The EI mass spectrum of deangeloylrenieramycin M-22-formate (60).




Figure 63 The UV spectrum of deangeloylrenieramycin M-22-formate (60).




Figure 66 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-formate (**60**) in CDCl_3 .




Figure 71 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(3'-chloropropanoate) (**61**) in CDCl_3 .




Figure 72 The EI mass spectrum of deangeloylrenieramycin M-22-butyrate (62).




Figure 73 The UV spectrum of deangeloylrenieramycin M-22-butyrate (62) in MeOH.




Figure 74 The circular dichroism spectrum of deangeloylrenieramycin M-22-butyrate (**62**) in MeOH.




Figure 75 The IR spectrum of deangeloylrenieramycin M-22-butyrate (**62**) (CHCl₃).




Figure 78 The EI mass spectrum of deangeloylrenieramycin M-22-(2'-methylpropanoate) (**63**).




Figure 79 The UV spectrum of deangeloylrenieramycin M-22-(2'-methylpropanoate) (**63**) in MeOH.




Figure 80 The IR spectrum of deangelylrenieramycin M-22-(2'-methylpropanoate) (**63**) (CHCl_3).




Figure 81 The 500 MHz ^1H NMR spectrum of deangelylrenieramycin M-22-(2'-methylpropanoate) (**63**) in CDCl_3 .




Figure 82 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(2'-methylpropanoate) (63) in CDCl_3 .




Figure 85 The circular dichroism spectrum of deangeloylrenieramycin M-22-(2'-methylbutyrate) (**64**) in MeOH.




Figure 86 The IR spectrum of deangeloylrenieramycin M-22-(2'-methylbutyrate) (**64**) (CHCl_3).




Figure 87 The 500 MHz ^1H NMR spectrum of deangeloylrenieramycin M-22-(2'-methylbutyrate) (**64**) in CDCl_3 .




Figure 88 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(2'-methylbutyrate) (**64**) in CDCl_3 .




Figure 89 The EI mass spectrum of deangeloylrenieramycin M-22-hexanoate (65).




Figure 90 The UV spectrum of deangeloylrenieramycin M-22-hexanoate (65) in MeOH.




Figure 91 The circular dichroism spectrum of deangeloylrenieramycin M-22-hexanoate (**65**) in MeOH.




Figure 92 The IR spectrum of deangeloylrenieramycin M-22-hexanoate (**65**) (CHCl₃).




Figure 93 The 500 MHz ^1H NMR spectrum of deangeloylrenieramycin M-22-hexanoate (**65**) in CDCl_3 .




Figure 94 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-hexanoate (**65**) M in CDCl_3 .




Figure 95 The EI mass spectrum of deangeloylrenieramycin M-22-heptanoate (66).




Figure 96 The UV spectrum of deangeloylrenieramycin M-22-heptanoate (66) in MeOH.




Figure 97 The circular dichroism spectrum of deangeloylrenieramycin M-22-heptanoate (66) in MeOH.




Figure 98 The IR spectrum of deangeloylrenieramycin M-22-heptanoate (66) (CHCl₃).




Figure 99 The 500 MHz ^1H NMR spectrum of deangeloylrenieramycin M-22-heptanoate (**66**) in CDCl_3 .




Figure 100 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-heptanoate (**66**) in CDCl_3 .




Figure 101 The EI mass spectrum of deangeloylrenieramycin M-22-(3'-methyl-2'-butenoate) (67).




Figure 102 The UV spectrum of deangeloylrenieramycin M-22-(3'-methyl-2'-butenoate) (67) in MeOH.




Figure 103 The circular dichroism spectrum of deangeloylrenieramycin M-22-(3'-methyl-2'-butenoate) (**67**) in MeOH.




Figure 104 The IR spectrum of deangeloylrenieramycin M-22-(3'-methyl-2'-butenoate) (**67**) (CHCl₃).




Figure 107 The EI mass spectrum of deangeloylrenieramycin M-22-(cyclopentane-1'-carboxylate) (68).




Figure 108 The UV spectrum of deangeloylrenieramycin M-22-(cyclopentane-1'-carboxylate) (68) in MeOH.




Figure 109 The circular dichroism spectrum of deangeloylrenieramycin M-22-(cyclopentane-1'-carboxylate) (**68**) in MeOH.




Figure 110 The IR spectrum of deangeloylrenieramycin M-22-(cyclopentane-1'-carboxylate) (**68**) (CHCl₃).




Figure 111 The 500 MHz ^1H NMR spectrum of deangeloylrenieramycin M-22-(cyclopentane-1'-carboxylate) (**68**) in CDCl_3 .




Figure 112 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(cyclopentane-1'-carboxylate) (**68**) in CDCl_3 .




Figure 113 The EI mass spectrum of deangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (69).




Figure 114 The UV spectrum of deangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (69) in MeOH.




Figure 115 The circular dichroism spectrum of deangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (**69**) in MeOH.




Figure 116 The IR spectrum of deangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (**69**) (CHCl₃).




Figure 117 The 500 MHz ^1H NMR spectrum of deangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (**69**) in CDCl_3 .




Figure 118 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (**69**) in CDCl_3 .




Figure 119 The EI mass spectrum of deangeloylrenieramycin M-22-(1'-cyclopentene-1'-carboxylate) (70).




Figure 120 The UV spectrum of deangeloylrenieramycin M-22-(1'-cyclopentene-1'-carboxylate) (70) in MeOH.




Figure 121 The circular dichroism spectrum of deangeloylrenieramycin M-22-(1'-cyclopentene-1'-carboxylate) (70) in MeOH.




Figure 122 The IR spectrum of deangeloylrenieramycin M-22-(1'-cyclopentene-1'-carboxylate) (70) (CHCl_3).




Figure 123 The 500 MHz ^1H NMR spectrum of deangeloylrenieramycin M-22-(1'-cyclopentene-1'-carboxylate) (**70**) in CDCl_3 .




Figure 124 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(1'-cyclopentene-1'-carboxylate) (**70**) in CDCl_3 .




Figure 127 The circular dichroism spectrum of deangeloylrenieramycin M-22-(3'-cyclopentene-1'-carboxylate) (**71**) in MeOH.




Figure 128 The IR spectrum of deangeloylrenieramycin M-22-(3'-cyclopentene-1'-carboxylate) (**71**) (CHCl₃).




Figure 131 The EI mass spectrum of deangeloylrenieramycin M-22-(1'-cyclohexene-1'-carboxylate) (72).




Figure 132 The UV spectrum of deangeloylrenieramycin M-22-(1'-cyclohexene-1'-carboxylate) (72) M in MeOH.




Figure 133 The circular dichroism spectrum of deangeloylrenieramycin M-22-(1'-cyclohexene-1'-carboxylate) (72) in MeOH.




Figure 134 The IR spectrum of deangeloylrenieramycin M-22-(1'-cyclohexene-1'-carboxylate) (72) (CHCl_3).




Figure 135 The 500 MHz ^1H NMR spectrum of deangeloylrenieramycin M-22-(1'-cyclohexene-1'-carboxylate) (72) M in CDCl_3 .




Figure 136 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(1'-cyclohexene-1'-carboxylate) (72) in CDCl_3 .




Figure 137 The EI mass spectrum of deangeloylrenieramycin M-22-(3'-cyclohexene-1'-carboxylate) (73).




Figure 138 The UV spectrum of deangeloylrenieramycin M-22-(3'-cyclohexene-1'-carboxylate) (73) in MeOH.




Figure 139 The circular dichroism spectrum of deangeloylrenieramycin M-22-(3'-cyclohexene-1'-carboxylate) (**73**) in MeOH.




Figure 140 The IR spectrum of deangeloylrenieramycin M-22-(3'-cyclohexene-1'-carboxylate) (**73**) (CHCl₃).




Figure 141 The 500 MHz ^1H NMR spectrum of deangeloylrenieramycin M-22-(3'-cyclohexene-1'-carboxylate) (**73**) in CDCl_3 .




Figure 142 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(3'-cyclohexene-1'-carboxylate) (**73**) in CDCl_3 .




Figure 143 The EI mass spectrum of deangeloylrenieramycin M-22-phenylcarboxylate (74).




Figure 144 The UV spectrum of deangeloylrenieramycin M-22-phenylcarboxylate (74) in MeOH.




Figure 145 The IR spectrum of deangeloylrenieramycin M-22-phenylcarboxylate (**74**) (CHCl_3).




Figure 146 The 300 MHz ¹H NMR spectrum of deangeloylrenieramycin M-22-phenylcarboxylate (**74**) in CDCl_3 .




Figure 147 The 75 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-phenylcarboxylate (74) in CDCl_3 .




Figure 148 The FAB mass spectrum of deangeloylrenieramycin M-22-(2'-methoxyphenylcarboxylate) (75).




Figure 149 The UV spectrum of deangeloylrenieramycin M-22-(2'-methoxyphenylcarboxylate) (75) in MeOH.




Figure 150 The IR spectrum of deangeloylrenieramycin M-22-(2'-methoxyphenylcarboxylate) (**75**) (CHCl₃).




Figure 151 The 300 MHz ¹H NMR spectrum of deangeloylrenieramycin M-22-(2'-methoxyphenylcarboxylate) (**75**) in CDCl₃.




Figure 152 The 75 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(2'-methoxyphenylcarboxylate) (75) in CDCl_3 .




Figure 153 The EI mass spectrum of deangeloylrenieramycin M-22-(4'-methoxyphenylcarboxylate) (76).




Figure 154 The UV spectrum of deangeloylrenieramycin M-22-(4'-methoxyphenylcarboxylate) (76) in MeOH.




Figure 155 The IR spectrum of deangeloylrenieramycin M-22-(4'-methoxyphenylcarboxylate) (**76**) (CHCl₃).




Figure 156 The 300 MHz ¹H NMR spectrum of deangeloylrenieramycin M-22-(4'-methoxyphenylcarboxylate) (**76**) in CDCl₃.




Figure 157 The 75 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(4'-methoxyphenylcarboxylate) (**76**) in CDCl_3 .




Figure 158 The 300 MHz NOESY spectrum of deangeloylrenieramycin M-22-(4'-methoxyphenylcarboxylate) (**76**) in CDCl_3 .




Figure 159 The FAB mass spectrum of deangeloylrenieramycin M-22-(4'-nitrophenylcarboxylate) (77).




Figure 160 The UV spectrum of deangeloylrenieramycin M-22-(4'-nitrophenylcarboxylate) (77) in MeOH.




Figure 161 The IR spectrum of deangeloylrenieramycin M-22-(4'-nitrophenyl-carboxylate) (77) (CHCl₃).




Figure 162 The 300 MHz ¹H NMR spectrum of deangeloylrenieramycin M-22-(4'-nitrophenylcarboxylate) (77) in CDCl₃.




Figure 163 The 75 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(4'-nitrophenylcarboxylate) (77) in CDCl_3 .




Figure 164 The FAB mass spectrum of deangeloylrenieramycin M-22-(4'-quinolinylcarboxylate) (78).




Figure 165 The UV spectrum of deangeloylrenieramycin M-22-(4'-quinolinylcarboxylate) (78) in MeOH.




Figure 168 The 125 MHz ^{13}C NMR spectrum of deangeloylrenieramycin M-22-(4'-quinolinylcarboxylate) (**78**) in CDCl_3 .




Figure 169 The 500 MHz NOESY of deangeloylrenieramycin M-22-(4'-quinolinylcarboxylate) (**78**) in CDCl_3 .




Figure 170 The FAB mass spectrum of 21-hydroxydeangeloylrenieramycin M-22-(3'-methyl-2'-butenoate) (79).




Figure 171 The IR spectrum of 21-hydroxydeangeloylrenieramycin M-22-(3'-methyl-2'-butenoate) (79) ($CHCl_3$).




Figure 172 The 500 MHz ^1H NMR spectrum of 21-hydroxydeangeloylrenieramycin M-22-(3'-methyl-2'-butenoate) (**79**) in CDCl_3 .




Figure 173 The 125 MHz ^{13}C NMR spectrum of 21-hydroxydeangeloylrenieramycin M-22-(3'-methyl-2'-butenoate) (**79**) in CDCl_3 .




Figure 174 The FAB mass spectrum of 21-hydroxydeangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (**80**).




Figure 175 The IR spectrum of 21-hydroxydeangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (**80**) ($CHCl_3$).




Figure 176 The 500 MHz ^1H NMR spectrum of 21-hydroxydeangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (**80**) in CDCl_3 .




Figure 177 The 125 MHz ^{13}C NMR spectrum of 21-hydroxydeangeloylrenieramycin M-22-(cyclohexane-1'-carboxylate) (**80**) in CDCl_3 .

VITA

Miss Kornvika Charupant was born on September 2, 1973 in Bangkok, Thailand. She received her Bachelor's Degree of Science in Pharmacy in 1997 from the Faculty of Pharmaceutical Sciences, Prince of Songkhla University, Thailand and Master's Degree of Science in Pharmacy in 2000 from the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Since her graduation, she has been working as a pharmacist at the Bureau of Drugs and Narcotics, Department of Medical Sciences, Ministry of Public Health.

Publications:

1. Charupant, K., Suwanborirux, K., Amnuoypol, S., Saito, E., Kubo, A., and Saito, N. 2007. Jorunnamycins A-C, new stabilized renieramycin-type bistetrahydroisoquinolines isolated from the Thai nudibranch *Jorunna funebris*. Chem. Pharm. Bull. 55 (1): 81-86.
2. Charupant, K., Suwanborirux, K., Amnuoypol, S., Saito, E., Daikuhara N., Owa, T., and Saito, N. 2007. Preparation and cytotoxic activity of renieramycin derivatives. J. Med. Chem. (In preparation).
3. Charupant, K., Suwanborirux, K., Amnuoypol, S., Daikuhara N., Ushijima, R., Kawai, T., Owa, T., and Saito, N. 2007. Comparison of the cytotoxicity of the marine bistetrahydroisoquinolines, renieramycin M and jorunnamycin C by gene expression analysis. J. Med. Chem. (In preparation).

Oral presentations:

1. Charupant, K. Chemical constituents of the Thai nudibranch *Jorunna funebris* and chemical modifications of renieramycin M and jorunnamycin A. The 30th anniversary graduate students MPU, December 10, 2005, Meiji Pharmaceutical University, Tokyo, Japan.
2. Charupant, K. Renieramycin acyl analogs and cytotoxicity evaluations. RGJ-Ph.D. Congress VIII, April 20-22, 2007, Pattaya, Choburi, Thailand.